EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Sezer, A.Kilickap, S.Gumus, M.Bondarenko, I.ÖZGÜROĞLU, MustafaGogishvili, M.TÜRK, HACI MEHMETCicin, I.Bentsion, D.Gladkov, O.Clingan, P.Sriuranpong, V.Rizvi, N.Li, S.Lee, S.Gullo, G.Lowy, I.Rietschel, P.2020-11-112020-11-112020-09-01http://hdl.handle.net/20.500.12645/27357Sezer A., Kilickap S., Gumus M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al., -EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%-, ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%Conference PaperWOS:00057346910268310.1016/j.annonc.2020.08.2285